Actavis' superbug antibiotic gets U.S. approval

The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. As a standalone medication, it is used to treat urinary tract infections. Concerns about superbugs have escalated, especially after the UCLA Health System said last week that seven patients were infected with a potentially deadly, drug-resistant strain of the Enterobacteriaceae bacteria, and that more than 100 people might have been exposed to it. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli & Co analyst Kevin Kedra believes there is room for multiple players.



via Health News Headlines - Yahoo News http://ift.tt/1BWHRZd